Reports Q4 revenue $121.62M, consensus $109.49M. “We are proud of our 2024 results as we delivered 83% year over year revenue growth while achieving profitability, investing in our pipeline, and continuing to build our infrastructure to capitalize on our highly differentiated technology and service offering,” said Waleed Hassanein, MD, President and Chief Executive Officer. “We stand firmly by our business and our dedicated, world-class NOP surgical and clinical leadership and team. We are humbled by and proud of the significant life-saving impact of our OCS technology and NOP teams, and we remain committed to our mission of expanding access and improving clinical outcomes to patients in need of organ transplants.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group options imply 16.2% move in share price post-earnings
- Shareholders that lost money on TransMedics Group, Inc.(TMDX) should contact Levi & Korsinsky LLP about pending Class Action – TMDX
- Short Report: Bears take aim at MobilEye with new highs in short interest
- Oppenheimer says TransMedics short report allegations not supported by checks
- TransMedics says claims made by Scorpion Capital ‘have no merit’